PURPOSE
TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with advanced thyroid (TC) or biliary tract cancer (BTC) with BRAF V600E mutations treated with cobimetinib pl...
Samantha A. Diamond-Rossi, M. Rothe, E. Garrett-Mayer et al.· JCO Precision Oncology· 0 citations
PURPOSE
TAPUR is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of two cohorts of patients with various solid tumors with FGFR1 or FGFR2 alterations treated with sunitinib are reported.
METHODS
Eligi...
Gordan Srkalovic, M. Rothe, E. Garrett-Mayer et al.· JCO Precision Oncology· 0 citations
A phase 2 clinical trial investigating neoadjuvant zanidatamab (HER2-targeting antibody) in patients with early-stage HER2-positive breast cancer found de-escalation to HER2-targeted therapy alone may be feasible.
V. Valero, P. Pohlmann, J. Mouabbi et al.· Nature Communications· 0 citations
This approach identified a unique peptide corresponding to FGFR2b, a splicing isoform of FGFR2, that demonstrated markedly higher tumor enrichment than the alternative FGFR2 isoform, FGFR2c.
N. Shah, Beatriz Alvarado-Hernandez, Xinyue Chen et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.